Contineum Therapeutics, Inc.

CTNM

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$376M

EPS-$1.76

P/E-5.56

P/FCF-7.20

EV/EBITDA-1.90

FCF Yield–

Div. Yield–

Net Debt/FCF4.6x

Contineum Therapeutics, Inc. intrinsic value

52-Week Range

$7.08$17.57

Profitability & Returns

TTM as of 2026-09 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$63M

▼ -41.9% YoY

Op. Margin

–

ROIC

-22.34%

▲ +16.5pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$52M

▼ -66.5% YoY

Op. Cash Flow (TTM)

-$52M

▼ -68.4% YoY

Net Debt

-$238M

Net Cash Position

Cash & Equiv.

$244M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with CTNM

CompareIntrinsic value

KALVKalVista Pharmaceuticals Inc.

No recent price25

XOMAXOMA Corporation

€0.05-3.60%64

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

SPROSpero Therapeutics Inc.

$1.07+2.88%63

GOSSGossamer Bio Inc.

$9.40+1.29%10

SIGASiga Technologies Inc.

$3.15+1.29%20

QTTBQ32 Bio Inc.

$8.97+2.40%60

Held by ETFs

CTNM is in 10 US ETFs. The largest of them, with CTNM's weight in each:

Contineum Therapeutics (CTNM) in three numbers

Quality score: 10/100; Best check: net debt, -$238M. Weakest: return on capital, -22.3%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -5.56; Negative: a loss over the last twelve months. Price to free cash flow -7.20.; Financials

Questions about Contineum Therapeutics

Is Contineum Therapeutics a high-quality business?

Contineum Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$238M, and its weakest is return on capital at -22.3%. The Quality tab shows every check against its target.

Does Contineum Therapeutics (CTNM) pay a dividend?

No. Contineum Therapeutics (CTNM) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 3 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in CTNM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CTNM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.